glyHealth-IBD

GlyHealth-IBD is a prognostic and predictive biomarker to support clinical decision-making in IBD.   It is being developed by a consortium comprised of Avenna, our sister company Ludger and collaboration partners across the UK and Europe including the Translational Gastroenterology Unit (TGU), Oxford.

Ludger is our development partner for all the GlyHealth variants. The company specialises in glycomics technology to optimise the clinical performance of anti-inflammatory biologic drugs and track progression of inflammatory diseases (IDs).

During the GlyHealth-IBD programme we discovered that IBD-patients have aberrant blood plasma glycomics patterns that correlate with IBD-specific inflammatory processes.

This study has been carried out on over 400 patients and showed that GlyHealth-IBD reliably estimated IBD severity, future disease course and future need for treatment escalation in newly diagnosed IBD patients up to 18 months from testing. See the detailed results of our study here.

Our next steps are to test GlyHealth IBD capabilities as a precision medicine biomarker for two groups:

Biopharma

Test use of GlyHealth-IBD as a complementary biomarker of gut healing in clinical trials for anti-inflammatory drugs for IBD patients.

Ideally, this would include a range of therapeutic types including a biologic drug

Clinicians and Patients

Test capabilities of GlyHealth-IBD as a precision medicine biomarker of:

  1.  Current IBD severity
  2.  Disease prognosis and tracking
  3. Need for future treatment escalation of IBD patients, focusing on newly-diagnosed patients
  4. To identify immunofrail IBD patients at risk of experiencing poor health outcomes if they were to become infected with SARS-Cov-2 virus.

Interested in partnering with us?​